Copyright
©The Author(s) 2025.
World J Stem Cells. Jul 26, 2025; 17(7): 107080
Published online Jul 26, 2025. doi: 10.4252/wjsc.v17.i7.107080
Published online Jul 26, 2025. doi: 10.4252/wjsc.v17.i7.107080
Table 1 Summary table of key findings
EVs | Key components | Target disease | Research focus | Ref. |
Bone marrow MSC-derived extracellular vesicles | Phase 2 multicenter double-anonymized randomized placebo-controlled dosing trial | Respiratory failure rom COVID-19 | Clinical trial | Lightner et al[18] |
Human placental mesenchymal stromal cell-derived small extracellular vesicles | Double-blind, randomized, controlled clinical trial | Acute respiratory distress syndrome | Clinical trial | Zamanian et al[19] |
ExosCD47-HuR | Fusion gene CD47-HuR integrate into LO2 cells via antiviral infection | Hepatic ischemia/reperfusion injury | Engineered vesicles | Liu et al[20] |
CD9 engineered ExoSmart | Integrate CD47 p110-130 into the exosomal membrane by engineering CD9 E174 | Pancreatic ductal adenocarcinoma | Engineered vesicles | Creeden et al[21] |
BV2 mouse microglial cell line exosome | Functional oligopeptide-modified exosome loaded with doxorubicin | Glioblastoma | Engineered vesicles | Wang et al[25] |
Bone marrow MSCs derived exosomes | Genetically engineered exosomes expressing chondrocyte-affinity peptide on the surface | Cartilaginous endplate degeneration | Engineered vesicles | Lin et al[27] |
MSCs derived exosomes | Anchored cartilage targeting optimally charged arginine-rich cationic motifs into the anionic exosome bilayer | Osteoarthritis | Engineered vesicles | Zhang et al[28] |
Adipose-derived stem cell-exosome | Conjugate antitumor necrosis factor-α antibodies to the surface of adipose-derived stem cell-exosome | Corneal alkali burns | Engineered vesicles | Yu et al[29] |
MSCs derived exosomes | Using engineered exosome to modulate ER homeostasis for restoring the function of MSCs | Bone defects in diabetic patients | Engineered vesicles | Liu et al[30] |
siRNA encapsulated exosomes | UTMD can enhance the local delivery of exosomes via the cavitation effects | DOX-induced cardiomyopathy | UTMD-assisted exosomal delivery | Chen et al[33] |
The encapsulation of exosomes with ferric ions (Fe3+) and tannic acid | Tannic acid surface modification | Kumar et al[36] | ||
Tannic acid improves exosome ability to specifically target heart tissue | Heart diseases | Tannic acid surface modification | Shin et al[37] | |
MSCs derived exosomes | IONP-labeled exosomes intravenous injection followed by the application of a 12 Tesla magnetic field | Clinically relevant model of skin injury | Magnetic nanoparticles targeting | Li et al[39] |
Bone marrow MSCs derived exosomes | Magnetic guidance: The retention of injected IONP-MSC-derived NVs within the infarcted heart | Myocardial infarction | Magnetic nanoparticles targeting | Lee et al[40] |
Exosomes from neutrophils | Engineered exosomes selectively accumulate at the tumor sites under an external magnetic field | Tumor | Magnetic nanoparticles targeting | Zhang et al[41] |
Endogenous extracellular vesicles | Magnetic-guided accumulation of captured CD63-expressing exosomes | Myocardial infarction | Magnetic nanoparticles targeting | Liu et al[42] |
ANG peptide-modified engineered exosomes | MNP@BQR@ANG-EXOsiGPX4 platform enriched in the brain under magnetic field | Glioblastoma | Magnetic nanoparticles targeting | Li et al[43] |
Milk-derived exosomes | Milk exosomes are good carriers for chemotherapy drugs | Tumor | Oral administration | Munagala et al[47] |
Milk-derived exosomes | RSV-loaded milk-derived exosomes to enhance the RSV oral bioavailability | Colon inflammation | Oral administration | Esfahani et al[48] |
Yam-derived exosome-like nanovesicles | The orally administered YNVs can be transported through the GI tract and absorbed through the small intestine | Osteoporosis | Oral administration | Hwang et al[49] |
Tea leaves-derived exosome-like nanovesicles | Oral administration is significantly less toxic than intravenous administration | Breast cancer | Oral administration | Chen et al[50] |
Intranasal delivery provides a practical, noninvasive method for delivering therapeutic agents to the brain | Brain inflammatory-related diseases | Intranasal delivery | Zhuang et al[51] | |
Adipose MSC-EVs | Intranasally administered via intelligent hydrogel | Alzheimer’s disease | Intranasal delivery | Huang et al[52] |
Dandelion-derived extracellular vesicle-like nanoparticles | Gelatin methacrylate composite hydrogel | Delayed wound healing caused by bacterial infection | Vesicles patch | Tan et al[58] |
MSC derived exosomes | Chitosan-based composite hydrogel dressing | Full-thickness skin defects, diabetic wounds, and burn skin injury | Vesicles patch | Shang et al[59] |
An efficient strategy for delivering exosome-loaded nanoparticles under hypoxic conditions | Poor wound healing following trauma and surgical | Vesicles patch | Han et al[60] | |
MSCs derived exosomes | HA hydrogel coated with polydopamine and DP7 | Burn injuries | Vesicles patch | Yang et al[61] |
Curcumin-loaded exosome | An injectable self-healing biphasic hydrogel composed of carboxymethyl chitosan and pullulan | Flap necrosis | Local injection | Liu et al[62] |
Exosomes originating from decidual stromal cells | An alginate-based hydrogel scaffold system | Intrauterine adhesion | Local injection | Liang et al[63] |
dECM from human umbilical cord MSCs derived exosomes | Exo-dECM hydrogel is a promising therapeutic strategy for treating SCI | SCI | Local injection | Wang et al[64] |
Adipose stem cells derived exosomes | Injectable thermosensitive hydrogel system | Androgenic alopecia | Local injection | Xiong et al[65] |
Bone marrow MSCs derived exosomes | Exosome-loaded hydrogel microparticles using microfluidic technology | Bone fracture | Local injection | Pan et al[68] |
Hybrid exosome-liposome system | Hyaluronic acid-based hydrogel microspheres via microfluidic techniques | Osteoarthritis | Local injection | Chen et al[69] |
Adipose stem cells derived exosomes | Clinical efficacy of microneedle-based administration of exosome | Facial skin aging | Microneedles | Park et al[72] |
Adipose-derived stem cell extracellular vesicles | A chondroitin sulfate C-based dissolving microneedle | Rheumatoid arthritis | Microneedles | Bui et al[75] |
Bone marrow MSCs derived exosomes | A silk fibroin microneedle patch consisting of LPS-pre-Exos and zeolitic imidazolate framework-8 | Oral ulcers | Microneedles | Ge et al[76] |
MSCs derived exosomes | Gelatin methacrylate microneedles had excellent 3D-Exo loading capacity and enabled continuous 3D-Exo release to maintain effective therapeutic concentrations | Ischemia reperfusion | Microneedles | Zhang et al[77] |
Mice breast cancer cell line 4T1 derived exosomes | Nano EXOs loaded within porous microneedles were employed for precise delivery of the STING agonist MSA-2 (MEM) to the tumor site | Tumor | Microneedles | Chen et al[78] |
Platelet-derived exosomes | A methacrylate-modified decellularized dermal matrix hydrogel-based microneedle patch | Diabetic wounds | Microneedles | Cao et al[79] |
Microneedle system achieving a balance between mechanical robustness and solubility | Microneedles | Mu et al[80] | ||
MSCs derived exosomes | A novel core-shell microneedle patch | Scarless skin repair | Microneedles | Lyu et al[81] |
MSCs derived exosomes | A core-shell microneedle model | Osteoarthritis | Microneedles | Li et al[82] |
T cells derived exosomes | A nanovesicle-based delivery platform to promote the efficacy of chemotherapeutic drugs with fewer side effects | Non-small cell lung cancer | Nebulizing | Zheng et al[83] |
MSCs derived exosomes | Explored the safety of nebulized haMSC-EVs in healthy volunteers | Preclinical lung injury model | Nebulizing | Shi et al[84] |
MSCs derived exosomes | Nebulization of MSC-derived exosomes is a safe, effective, and simple method, and their application at the beginning of treatment may be more beneficial | COVID-19 pneumonia | Nebulizing | Chu et al[85] |
- Citation: Ye YL, Liu L. Engineering the future of nanomedicine: Strategic approaches to extracellular vesicle-based drug administration regimens. World J Stem Cells 2025; 17(7): 107080
- URL: https://www.wjgnet.com/1948-0210/full/v17/i7/107080.htm
- DOI: https://dx.doi.org/10.4252/wjsc.v17.i7.107080